Ignite Creation Date:
2024-05-06 @ 7:54 AM
Last Modification Date:
2024-10-26 @ 11:53 AM
Study NCT ID:
NCT02624570
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2020-07-15
First Post:
2015-12-03
Brief Title:
Midostaurin Access Program for Newly Diagnosed FLT3 ITD or TKD Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2015-12-03
First Submit QC Date:
December 3 2015
Study First Post Date:
2015-12-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-07-14
Last Update Post Date:
2020-07-15
Last Update Post Date Type:
ACTUAL